- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00684632
A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Kumamoto, Japan
-
Okayama, Japan
-
Toyama, Japan
-
Wakayama, Japan
-
-
Aichi
-
Nagoya, Aichi, Japan
-
-
Chiba
-
Katori, Chiba, Japan
-
-
Ehime
-
Matsuyama, Ehime, Japan
-
-
Fukuoka
-
Kitakyushu, Fukuoka, Japan
-
-
Fukushima
-
Koriyama, Fukushima, Japan
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan
-
-
Hyogo
-
Nishinomiya, Hyogo, Japan
-
-
Ibaraki
-
Kasama, Ibaraki, Japan
-
-
Ishikawa
-
Kanazawa, Ishikawa, Japan
-
-
Kyoto
-
Uji, Kyoto, Japan
-
-
Nagano
-
Azumino, Nagano, Japan
-
-
Osaka
-
Ibaraki, Osaka, Japan
-
Izumisano, Osaka, Japan
-
-
Tochigi
-
Mibu, Tochigi, Japan
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan
-
Shinagawa-ku, Tokyo, Japan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
At the time of obtaining written informed consent
- Provide written informed consent to participate in the study on a voluntary basis.
- Between the ages of 20 and 80 years (inclusive).
- Outpatients who live with a caregiver such as a family member, or inpatients.
- Regularly receiving one of the following opioid analgesics: sustained-release oral morphine, sustained-release oral oxycodone, and fentanyl transdermal patch.
- The daily dosage of the regular opioid analgesic regimen can be maintained constant from the baseline period through the end of the study as determined by the investigator.
- Require rescue medication at least 0.5 times (at least once every two days) but not more than three times per day on average as determined by the investigator.
- Performance Status (ECOG) of 3 or less at the time of giving written informed consent.Be able to receive diary training and have the ability to properly complete diaries as determined by the investigator.
- Have a life expectancy of at least three months as determined by the investigator.
- Be able to receive diary training and have the ability to properly complete diaries as determined by the investigator.
At the time of randomization
- The "regular opioid analgesic" being used at the time of giving written informed consent has been taken at a fixed dosage throughout the baseline period.
- The "immediate-release morphine" being used at the time of giving written informed consent (Opso® (morphine hydrochloride hydrate) oral solution, morphine hydrochloride (powder), or morphine hydrochloride tablets) has been taken at a fixed dosage of 5, 10, 15, or 20 mg/dose throughout the baseline period.
- Have received rescue medication at least 0.5 times but not more than three times per day on average during the baseline period.
- Have had a pain intensity of at least 3 cm as rated on a visual analog scale (VAS) immediately before each of two or more rescue doses of immediate-release morphine during the baseline period, and had a mean decrease of at least 1.8 cm and at least one-third in VAS-rated pain intensity at 30 minutes after dosing compared with the pre-dose value.
- Have received diary training and been able to properly complete diaries during the baseline period.
Exclusion Criteria:
At the time of obtaining written informed consent
- Intolerable adverse reactions (as defined in Attachment 3) to opioids.
- Serious respiratory dysfunction.
- Asthma.
- Serious bradyarrhythmia.
- Serious hepatic dysfunction.
- Serious renal dysfunction.
- Susceptibility to respiratory depression due to conditions such as increased intracranial pressure, head injury and brain tumor.
- Patients who have a history of clinically significant adverse reactions to the combination of opioid analgesics and any of the following drugs/substances, and who are currently receiving or expect to receive any of them during the study:
Central nervous system depressants (phenothiazines, benzodiazepines and barbiturates), inhalation anesthetics, monoamine oxidase inhibitors, tricyclic antidepressants, skeletal muscle relaxants, antihistamines, ritonavir, alcohol, itraconazole, amiodarone, clarithromycin, diltiazem, and fluvoxamine.
- History of convulsive seizures (except a single episode of infantile febrile convulsions).
- History of hypersensitivity to fentanyl.
- Current or past history of drug dependence or narcotic abuse.
- Pregnant or lactating women, possibly pregnant women, or women who are planning to become pregnant.
- Participation in any other clinical trial within 28 days prior to giving written informed consent.
- Prior exposure to KW-2246.
- Patients who are judged by the investigator/subinvestigator to be inappropriate for this study.
At the time of randomization
- Have experienced intolerable adverse reactions (as defined in Attachment 3) to opioids during the baseline period.
- Have received, during the baseline period, any morphine, oxycodone and fentanyl formulations other than the "regular opioid analgesic" being used at the time of giving written informed consent.
- Use of codeine, dihydrocodeine, opium, pethidine, buprenorphine, pentazocine, tramadol, butorphanol, and eptazocine within seven days prior to randomization (except codeine at daily dosages up to 60 mg and dihydrocodeine at daily dosages up to 30 mg for the treatment of cough).
- Interventions that may affect pain intensity rating, such as surgery, radiation therapy and nerve bThe daily dosages of systemically-acting adjuvant analgesics or drugs with analgesic activity have been modified during the baseline period.lock, within seven days prior to randomization.
- Use of narcotic antagonists within seven days prior to randomization.
- The daily dosages of systemically-acting adjuvant analgesics or drugs with analgesic activity have been modified during the baseline period.
- The daily dosages of locally-acting adjuvant analgesics or drugs with analgesic activity being used for the relief of cancer pain have been modified during the baseline period.
- The daily dosages of codeine (up to 60 mg/day) and dihydrocodeine (up to 30 mg/day) being used for the treatment of cough have been modified during the baseline period.
- Have the following results in the most recent laboratory tests conducted within seven days prior to randomization:
AST >5 times the upper limit of normal at each study site (ULN); ALT >5 times ULN; or Serum creatinine >1.5 times ULN.
- Dry mouth that affects sublingual administration (i.e., poor compliance during sublingual administration training with placebo).
- Subjects who are judged by the investigator/subinvestigator to be inappropriate for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 2
Placebo
|
Placebo
|
Experimental: 1
KW-2246
|
KW-2246 (fentanyl citrate)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Breakthrough Pain
- Cancer Pain
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Analgesics, Opioid
- Narcotics
- Adjuvants, Anesthesia
- Fentanyl
Other Study ID Numbers
- 2246-0702
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain, Cancer
-
Kyowa Kirin Co., Ltd.Completed
-
University Hospital, Basel, SwitzerlandTerminatedCancer: Breakthrough Pain | Cancer: Extreme Pain on MovementSwitzerland
-
University of UtahCompletedCancer-associated PainUnited States
-
University of JordanCompleted
-
Laboratoires Bouchara-RecordatiUnknown
-
University of PittsburghCompletedMetastatic Cancer | Invasive Cancer | Pain, CancerUnited States
-
Wex Pharmaceuticals Inc.Completed
-
Sorrento Therapeutics, Inc.WithdrawnPain, Intractable | Pain Cancer
-
Institut CurieRecruitingCancer Patients With Cancer PainFrance
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States